These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22223479)

  • 1. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
    Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
    Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P
    Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.
    Toedter G; Li K; Marano C; Ma K; Sague S; Huang CC; Song XY; Rutgeerts P; Baribaud F
    Am J Gastroenterol; 2011 Jul; 106(7):1272-80. PubMed ID: 21448149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway.
    De Preter V; Arijs I; Windey K; Vanhove W; Vermeire S; Schuit F; Rutgeerts P; Verbeke K
    Inflamm Bowel Dis; 2012 Jun; 18(6):1127-36. PubMed ID: 21987487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular patterns in human ulcerative colitis and correlation with response to infliximab.
    Halloran B; Chang J; Shih DQ; McGovern D; Famulski K; Evaschesen C; Fedorak RN; Thiesen A; Targan S; Halloran PF
    Inflamm Bowel Dis; 2014 Dec; 20(12):2353-63. PubMed ID: 25397893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis.
    De Preter V; Arijs I; Windey K; Vanhove W; Vermeire S; Schuit F; Rutgeerts P; Verbeke K
    Inflamm Bowel Dis; 2012 Dec; 18(12):2371-80. PubMed ID: 22434643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis.
    Gundersen MD; Goll R; Fenton CG; Anderssen E; Sørbye SW; Florholmen JR; Paulssen RH
    Clin Transl Gastroenterol; 2019 Oct; 10(10):e00082. PubMed ID: 31584460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
    Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
    Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
    Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
    Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
    Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
    Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
    Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
    Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional analysis of left-sided colitis, pancolitis, and ulcerative colitis-associated dysplasia.
    Bjerrum JT; Nielsen OH; Riis LB; Pittet V; Mueller C; Rogler G; Olsen J
    Inflamm Bowel Dis; 2014 Dec; 20(12):2340-52. PubMed ID: 25358065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis.
    Coskun M; Olsen AK; Holm TL; Kvist PH; Nielsen OH; Riis LB; Olsen J; Troelsen JT
    Biochim Biophys Acta; 2012 Jun; 1822(6):843-51. PubMed ID: 22326557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations.
    Planell N; Lozano JJ; Mora-Buch R; Masamunt MC; Jimeno M; Ordás I; Esteller M; Ricart E; Piqué JM; Panés J; Salas A
    Gut; 2013 Jul; 62(7):967-76. PubMed ID: 23135761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.